Memphasys Past Earnings Performance

Past criteria checks 0/6

Memphasys's earnings have been declining at an average annual rate of -31.1%, while the Life Sciences industry saw earnings growing at 19.5% annually. Revenues have been growing at an average rate of 61.2% per year.

Key information

-31.1%

Earnings growth rate

-12.2%

EPS growth rate

Life Sciences Industry Growth19.7%
Revenue growth rate61.2%
Return on equity-68.3%
Net Margin-613.8%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Memphasys (ASX:MEM) Is Making Moderate Use Of Debt

Mar 01
Memphasys (ASX:MEM) Is Making Moderate Use Of Debt

Memphasys (ASX:MEM) Is Making Moderate Use Of Debt

Jun 13
Memphasys (ASX:MEM) Is Making Moderate Use Of Debt

Does Memphasys (ASX:MEM) Have A Healthy Balance Sheet?

Jun 20
Does Memphasys (ASX:MEM) Have A Healthy Balance Sheet?

Is Memphasys (ASX:MEM) A Risky Investment?

Feb 28
Is Memphasys (ASX:MEM) A Risky Investment?

Memphasys (ASX:MEM) Is Making Moderate Use Of Debt

Sep 01
Memphasys (ASX:MEM) Is Making Moderate Use Of Debt

Will Memphasys (ASX:MEM) Spend Its Cash Wisely?

Jan 07
Will Memphasys (ASX:MEM) Spend Its Cash Wisely?

Revenue & Expenses Breakdown
Beta

How Memphasys makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ASX:MEM Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 231-522
30 Sep 231-412
30 Jun 231-311
31 Mar 231-311
31 Dec 221-211
30 Sep 221-211
30 Jun 221-211
31 Mar 221-211
31 Dec 211-211
30 Sep 210-211
30 Jun 210-110
31 Mar 210-110
31 Dec 200-110
30 Sep 200-110
30 Jun 200-110
31 Mar 200-110
31 Dec 190-110
30 Sep 190-110
30 Jun 190-110
31 Mar 190-110
31 Dec 180-110
30 Sep 180-110
30 Jun 180010
31 Mar 180-110
31 Dec 170-120
30 Sep 170-120
30 Jun 170-220
31 Mar 170-210
31 Dec 160-220
30 Sep 160-220
30 Jun 160-220
31 Dec 150-210
30 Sep 150-210
30 Jun 150-220
31 Dec 140-110
30 Sep 140-110
30 Jun 140-110
31 Dec 131-321
30 Sep 131-321
30 Jun 131-221

Quality Earnings: MEM is currently unprofitable.

Growing Profit Margin: MEM is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: MEM is unprofitable, and losses have increased over the past 5 years at a rate of 31.1% per year.

Accelerating Growth: Unable to compare MEM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MEM is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (0.2%).


Return on Equity

High ROE: MEM has a negative Return on Equity (-68.34%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.